These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 28609624)

  • 1. In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development.
    Lombardo F; Desai PV; Arimoto R; Desino KE; Fischer H; Keefer CE; Petersson C; Winiwarter S; Broccatelli F
    J Med Chem; 2017 Nov; 60(22):9097-9113. PubMed ID: 28609624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADME-Space: a new tool for medicinal chemists to explore ADME properties.
    Bocci G; Carosati E; Vayer P; Arrault A; Lozano S; Cruciani G
    Sci Rep; 2017 Jul; 7(1):6359. PubMed ID: 28743970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting ADME properties in silico: methods and models.
    Butina D; Segall MD; Frankcombe K
    Drug Discov Today; 2002 Jun; 7(11):S83-8. PubMed ID: 12047885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery.
    Khakar PS
    Curr Top Med Chem; 2010; 10(1):116-26. PubMed ID: 19929825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic properties and in silico ADME modeling in drug discovery.
    Honório KM; Moda TL; Andricopulo AD
    Med Chem; 2013 Mar; 9(2):163-76. PubMed ID: 23016542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives.
    Bolleddula J; Brady K; Bruin G; Lee A; Martin JA; Walles M; Xu K; Yang TY; Zhu X; Yu H
    Drug Metab Dispos; 2022 Jun; 50(6):837-845. PubMed ID: 35149541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15.
    Boobis A; Gundert-Remy U; Kremers P; Macheras P; Pelkonen O
    Eur J Pharm Sci; 2002 Dec; 17(4-5):183-93. PubMed ID: 12453607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models.
    Moda TL; Torres LG; Carrara AE; Andricopulo AD
    Bioinformatics; 2008 Oct; 24(19):2270-1. PubMed ID: 18684738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in predicting human ADME parameters in silico.
    Ekins S; Waller CL; Swaan PW; Cruciani G; Wrighton SA; Wikel JH
    J Pharmacol Toxicol Methods; 2000; 44(1):251-72. PubMed ID: 11274894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug metabolism and pharmacokinetics in drug discovery.
    Roberts SA
    Curr Opin Drug Discov Devel; 2003 Jan; 6(1):66-80. PubMed ID: 12613278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods.
    Tsaioun K; Blaauboer BJ; Hartung T
    ALTEX; 2016; 33(4):343-358. PubMed ID: 27806179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-ADME relationship: still a long way to go?
    Hou T; Wang J
    Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):759-70. PubMed ID: 18611116
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ekins S; Lane TR; Urbina F; Puhl AC
    Xenobiotica; 2024 Jul; 54(7):352-358. PubMed ID: 37539466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders.
    Volak LP; Duevel HM; Humphreys S; Nettleton D; Phipps C; Pike A; Rynn C; Scott-Stevens P; Zhang D; Zientek M
    Drug Metab Dispos; 2023 Jul; 51(7):792-803. PubMed ID: 37041086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Critique of Computer Simulation Software's Used in Pharmacokinetics and Pharmacodynamics Analysis.
    Dave V; Yadav RB; Yadav S; Sharma S; Sahu RK; Ajayi AF
    Curr Clin Pharmacol; 2018; 13(4):216-235. PubMed ID: 30360723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability.
    Gombar VK; Silver IS; Zhao Z
    Curr Top Med Chem; 2003; 3(11):1205-25. PubMed ID: 12769701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico ADME/T modelling for rational drug design.
    Wang Y; Xing J; Xu Y; Zhou N; Peng J; Xiong Z; Liu X; Luo X; Luo C; Chen K; Zheng M; Jiang H
    Q Rev Biophys; 2015 Nov; 48(4):488-515. PubMed ID: 26328949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools.
    Tao L; Zhang P; Qin C; Chen SY; Zhang C; Chen Z; Zhu F; Yang SY; Wei YQ; Chen YZ
    Adv Drug Deliv Rev; 2015 Jun; 86():83-100. PubMed ID: 26037068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive DMPK: in silico ADME predictions in drug discovery.
    Kenny JR
    Mol Pharm; 2013 Apr; 10(4):1151-2. PubMed ID: 23540938
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.